In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Simulations Plus (SLP – Research Report). The company’s shares closed yesterday at $50.25.
According to TipRanks, Hewitt is an analyst with an average return of -2.9% and a 46.42% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Avid Bioservices, BioLife Solutions, and Apyx Medical.
Simulations Plus has an analyst consensus of Moderate Buy.
Based on Simulations Plus’ latest earnings release for the quarter ending February 29, the company reported a quarterly revenue of $18.31 million and a net profit of $4.03 million. In comparison, last year the company earned a revenue of $15.75 million and had a net profit of $4.17 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Simulations Plus (SLP) Company Description:
Simulations Plus, Inc. engages in licensing and conducting drug research by pharmaceutical and biotechnology companies. It offers pharmaceutical, and chemical, cosmetics and food industries. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered Lancaster, CA.
Read More on SLP:
- Simulations Plus (NASDAQ:SLP): Promising Potential in Biotech Software
- Simulations Plus announces U.S. FDA renewed license to DILIsym platform
- Simulations Plus backs FY24 EPS view 66c-68c, consensus 66c
- Simulations Plus reports Q2 EPS 20c, consensus 19c
- Simulations Plus Q2 Financial Performance and Outlook Warning
